The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
7
Weekly IV infusion for 3 consecutive weeks in a 4-week cycle
MAYO Clinic
Scottsdale, Arizona, United States
The Robert H Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States
Hôpital Huriez, Centre Hospitalier Régional Universitaire de Lille
Lille, France
University Hospital Hôtel-Dieu
Nantes, France
Response Rate according to International Myeloma Working Group uniform response criteria for multiple myeloma.
Time frame: At end of each cycle
Overall safety profile
Time frame: All cycles
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.